查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球主動植入醫療器材市場 -2023-2030
市場調查報告書
商品編碼
1373372

全球主動植入醫療器材市場 -2023-2030

Global Active Implantable Medical Devices Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

主動式植入式醫療器械是指為了診斷或治療目的而全部或部分引入人體的主動醫療器械。主動植入式醫療設備包括多種設備，包括心律調節器、除顫器、輸液幫浦、心室輔助系統和設備、人工耳蝸和神經刺激器。

有源植入式醫療設備旨在長時間與身體直接接觸，並遵守嚴格的標準和要求，以保護患者的健康和安全。有源植入式醫療設備也廣泛應用於心血管、神經病學和骨科等各種領域。

市場動態

增加設備發布

主動式植入式醫療器材產品的推出數量不斷增加，成為市場成長的重要推手。此外，許多主要參與者透過推出新的治療設備在市場的進步中發揮重要作用。

例如，2023 年 5 月，微創 CRM 的最新系列植入式心律調節器 AlizeaTM 和 CeleaTM 獲得美國 FDA 批准。這些是現代起搏器技術，在皮膚下體積小且離散，更容易植入。

此外，2022年12月，美敦力推出了一款名為Percept PC的深部腦植入式刺激器，配備了名為BrainSense的技術，可為帕金森氏症等神經系統疾病患者提供電深部腦部刺激（DBS ）治療。

此外，2022 年 8 月，美敦力 (Medtronic) 公司。推出血管外植入式心律轉復除顫器 (EV ICD) 系統去顫器，導線置於胸骨下方。

此外，慢性病盛行率和發病率上升以及使用主動植入醫療設備進行微創手術的日益普及等重要成長動力預計將在預測期內推動市場發展。

與植入式起搏器相關的併發症

與植入心律調節器相關的併發症將阻礙預測期內的市場成長。根據梅奧診所的說法，起搏器部位可能會出現腫脹、出血或瘀傷，尤其是在患者服用血液稀釋劑的情況下。它也可能導致起搏器部位附近的血栓栓塞（血塊）或起搏器附近的血管或神經損傷。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按設備類型分類
  • 按應用程式片段
  • 最終用戶摘錄
  • 按地區分類

第 4 章：市場動態

  • 影響因素
    • 促進要素
      • 增加設備發布
      • YY
    • 限制
      • 與植入式起搏器相關的併發症
      • YY
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按裝置類型

  • 植入式心臟復律去顫器
    • 經靜脈植入式心臟復律去顫器
      • 雙心室植入式心臟復律去顫器
      • 雙腔植入式心臟復律去顫器
      • 單腔植入式心臟復律去顫器
    • 皮下植入式心臟復律去顫器
  • 植入式心臟節律器
  • 心室輔助裝置
  • 神經刺激器
  • 植入式聽力設備
  • 植入式心臟監測儀
  • 植入式血糖監測儀

第 8 章：按應用

  • 心血管
  • 神經病學
  • 骨科
  • 其他

第 9 章：最終用戶

  • 醫院
  • 門診手術中心
  • 心臟中心
  • 神經中心
  • 其他

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Boston Scientific Corporation
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Medtronic Plc
  • MED-EL
  • Nurotron Biotechnology Co. Ltd.
  • Abbott Laboratories
  • Cochlear Ltd
  • Sanova Holding AG
  • LivaNova Plc
  • Biotronik Inc.
  • Osypka Medical

第 13 章：附錄

簡介目錄
Product Code: MD1510

Overview

An active implantable medical device is an active medical device intended to be totally or partially introduced into the human body for diagnostic or therapeutic purposes. An active implantable medical device includes a wide range of devices, including pacemakers, defibrillators, infusion pumps, ventricular assist systems and devices, cochlear implants, and neurostimulators.

Active implantable medical devices are designed to remain in direct contact with the body for extended periods and they are subject to rigorous standards and requirements to protect the health and safety of patients. Active implantable medical devices are also widely used in various applications such as in the cardiovascular, neurology, and orthopedic.

Market Dynamics

Increasing device launches

The increasing number of product launches for active implantable medical devices acts as a significant driver for market growth. Also, many key players play a major role in the advancements of the market by launching new treatment devices.

For instance, in May 2023, MicroPort CRM received U.S. FDA approval for its latest range of implantable pacemakers, AlizeaTM and CeleaTM. These are modern pacemaker technology that is small and discrete under the skin, making it easier to implant.

Also, in December 2022, Medtronic launched a deep brain implantable stimulator called Percept PC which is equipped with technology called BrainSense to provide electrical deep brain stimulation (DBS) treatment to patients with neurological diseases such as Parkinson's disease.

Additionally, in August 2022, Medtronic plc. Launched an extravascular implantable cardioverter defibrillator (EV ICD) system defibrillator with a lead put under the breastbone.

Furthermore, significant growth drivers such as the rising prevalence and incidence of chronic diseases, and the growing adoption of minimally invasive surgeries by using active implantable medical devices are expected to drive the market in the forecast period.

Complications related to implantable pacemakers

The complications related to implanted pacemakers will hamper the market growth in the forecast period. As per the Mayo Clinic, swelling, bleeding, or bruising can occur at the pacemaker site, particularly if the patient is taking blood thinners. It can also cause thromboembolism (blood clots) near the pacemaker site or the blood vessel or nerve damage near the pacemaker.

Segment Analysis

The global active implantable medical devices market is segmented based on device type, application, end users, and region.

Neurostimulators accounted for approximately 47.3% of the market share

An implantable neurostimulator delivers mild electrical signals to the epidural space near the spine through thin wires called leads. Neurostimulators are expected to hold the largest market share over the period forecast owing to increasing new neurostimulator launches and technical advancements.

For instance, in April 2023, Synapse Biomedical, Inc. launched the NeuRx Diaphragm Pacing System which is a battery-powered device that delivers electrical stimulation via four percutaneous intramuscular electrodes implanted into the diaphragm with minimally invasive laparoscopy.

Additionally, in December 2022, Abbott launched the Eterna spinal cord stimulation (SCS) system which is the smallest implantable, rechargeable spinal cord stimulator for the treatment of chronic pain.

Geographical Analysis

North America is expected to hold a significant position in the global active implantable medical devices market share

The global active implantable medical devices market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of atrial fibrillation, and increasing adoption of cardiac pacemaker implantation, this trend is anticipated to continue throughout the forecast period.

For instance, according to the National Institute of Health 2022, it is estimated that in the United States, the number of people with an implantable pacemaker is between 500,000 and 3 million. The chance of pacemaker implantation increases with age for over 70% of all pacemakers that are implanted in patients over the age of 65.

Additionally, according to Healthline Media, it is estimated that the prevalence of atrial fibrillation in the United States ranges from about 2.7 million to 6.1 million. It is estimated to rise to 12.1 million in 2030. Hence, due to the increasing number of people with atrial fibrillation, the rate of pacemaker implantation is expected to increase to treat heart diseases.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global active implantable medical devices market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the active implantable medical devices market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Boston Scientific Corporation, Medtronic Plc, MED-EL, Nurotron Biotechnology Co. Ltd., Abbott Laboratories, Cochlear Ltd, Sanova Holding AG, LivaNova Plc, Biotronik Inc., Osypka Medical among others.

Key Developments

  • In June 2023, Medics invested £1.8 million for clinical trials with the aim of precisely targeting heart patients who need tiny defibrillators to be fitted under their skin with the aim of reducing deaths from sudden cardiac arrests.
  • In June 2021, India Medtronic Private Limited launched Micra AV, a little, a fully self-contained pacemaker that uses a minimally invasive method to provide sophisticated pacing technology to those with atrioventricular (AV) block.

Why Purchase the Report?

  • To visualize the global active implantable medical devices market segmentation based on device type, application, end users and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of active implantable medical devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global active implantable medical devices market report would provide approximately 61 tables, 62 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End Users
  • 3.4. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing device launches
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. Complications related to implantable pacemakers
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Implantable Cardioverter Defibrillators*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Transvenous Implantable Cardioverter Defibrillators
      • 7.2.3.1. Biventricular Implantable Cardioverter Defibrillators
      • 7.2.3.2. Dual-Chamber Implantable Cardioverter Defibrillators
      • 7.2.3.3. Single-Chamber Implantable Cardioverter Defibrillators
    • 7.2.4. Subcutaneous Implantable Cardioverter Defibrillators
  • 7.3. Implantable Cardiac Pacemakers
  • 7.4. Ventricular Assist Devices
  • 7.5. Neurostimulators
  • 7.6. Implantable Hearing Devices
  • 7.7. Implantable Heart Monitors
  • 7.8. Implantable Glucose Monitors

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Neurology
  • 8.4. Orthopedic
  • 8.5. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.1.2. Market Attractiveness Index, By End Users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Cardiac Centers
  • 9.5. Neuro Centers
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Boston Scientific Corporation
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Medtronic Plc
  • 12.3. MED-EL
  • 12.4. Nurotron Biotechnology Co. Ltd.
  • 12.5. Abbott Laboratories
  • 12.6. Cochlear Ltd
  • 12.7. Sanova Holding AG
  • 12.8. LivaNova Plc
  • 12.9. Biotronik Inc.
  • 12.10. Osypka Medical

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us